<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PYRIDOSTIGMINE BROMIDE- pyridostigmine bromideÂ tabletÂ </strong><br>KAISER FOUNDATION HOSPITALS<br></p></div>
<h1>Pyridostigmine Bromide Tablets, USP<br>60 mg<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">DESCRIPTION: </span>Pyridostigmine Bromide Tablet is an orally active <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitor. Chemically, pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. The molecular formula of pyridostigmine bromide is C<span class="Sub">9</span>H<span class="Sub">13</span>BrN<span class="Sub">2</span>O<span class="Sub">2</span> and molecular weight is 261.12. Its structural formula is:</p>
<div class="Figure"><img alt="Chem Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9448c360-0ce2-42fe-9f0c-50f2159e8483&amp;name=Pyridostigmine-01.jpg"></div>
<p>Each Pyridostigmine Bromide Tablet intended for oral administration contains 60 mg of Pyridostigmine Bromide USP. In addition, it also contains the following inactive ingredients: colloidal silicon dioxide, anhydrous lactose and stearic acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICALPHARMACOLOGY"></a><a name="section-2"></a><p></p>
<p class="First"><span class="Bold">CLINICAL PHARMACOLOGY</span><br>Pyridostigmine Bromide Tablets inhibits the destruction of acetylcholine by <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine, but differs from it in certain clinically significant respects; for example, pyridostigmine is characterized by a longer duration of action and fewer gastrointestinal side effects.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONSANDUSAGE"></a><a name="section-3"></a><p></p>
<p class="First"><span class="Bold">INDICATIONS AND USAGE</span><br>Pyridostigmine Bromide Tablets are useful in the treatment of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<p class="First"><span class="Bold">CONTRAINDICATIONS </span><br>Pyridostigmine Bromide Tablets are contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Care should be observed in the use of atropine for counteracting side effects, as discussed below.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-5"></a><p></p>
<p class="First"><span class="Bold">WARNINGS </span><br>Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. As is true of all cholinergic drugs, overdosage of Pyridostigmine Bromide Tablets may result in <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>, a state characterized by increasing <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> which, through involvement of the muscles of respiration, may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by extreme <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, and thus may be difficult to distinguish from <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> on a symptomatic basis. Such differentiation is extremely important, since increases in doses of Pyridostigmine Bromide Tablets or other drugs of this class in the presence of <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> or of a refractory or â€œinsensitiveâ€? state could have grave consequences. Osserman and Genkins<span class="Sup">1</span> indicate that the differential diagnosis of the two types of crisis may require the use of edrophonium chloride as well as clinical judgment. The treatment of the two conditions obviously differs radically. Whereas the presence of myasthenic crisis suggests the need for more intensive anticholinesterase therapy, the diagnosis of <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>, according to Osserman and Genkins<span class="Sup">1</span>, calls for the prompt <span class="Italics">withdrawal</span> of all drugs of this type. The immediate use of atropine in <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span> is also recommended.</p>
<p>Atropine may also be used to abolish or obtund gastrointestinal side effects or other muscarinic reactions; but such use, by masking signs of overdosage, can lead to inadvertent induction of <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>.</p>
<p>For detailed information on the management of patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, the physician is referred to one of the excellent reviews such as those by Osserman and Genkins,<span class="Sup">2</span> Grob<span class="Sup">3</span> or Schwab.<span class="Sup">4,5</span></p>
<p><span class="Italics">Usage in Pregnancy</span><br><span class="Italics">Pregnancy:</span> The safety of Pyridostigmine Bromide Tablets during pregnancy or lactation in humans has not been established. Therefore, use of Pyridostigmine Bromide Tablets in women who may become pregnant requires weighing the drugâ€™s potential benefits against its possible hazards to mother and child.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-6"></a><p></p>
<p class="First"><span class="Bold">PRECAUTIONS </span><br>Pyridostigmine is mainly excreted unchanged by the kidney.<span class="Sup">6,7,8</span> Therefore, lower doses may be required in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, and treatment should be based on titration of drug dosage to effect.<span class="Sup">6,7</span></p>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.1"></a><p></p>
<p class="First"><span class="Italics">Pediatric Use: </span>Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSEREACTIONS"></a><a name="section-7"></a><p></p>
<p class="First"><span class="Bold">ADVERSE REACTIONS </span><br>The side effects of Pyridostigmine Bromide Tablets are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, increased peristalsis, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="4010476" conceptname="Excessive bronchial secretion">increased bronchial secretions</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>. Nicotinic side effects are comprised chiefly of <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculation</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGEANDADMINISTRATION"></a><a name="section-8"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">DOSAGE AND ADMINISTRATION: </span>Pyridostigmine Bromide Tablets are available as tablet form; each containing 60 mg pyridostigmine bromide.</p>
<p><span class="Italics">Dosage: </span>The size and frequency of the dosage must be adjusted to the needs of the individual patient.</p>
<p>The average dose is ten 60-mg tablets daily, spaced to provide maximum relief when maximum strength is needed. In severe cases as many as 25 tablets a day may be required, while in mild cases one to six tablets a day may suffice.</p>
<p><span class="Italics">Note: </span>For information on a diagnostic test for <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, and for the evaluation and stabilization of therapy, please see product literature on Tensilon<span class="Sup">Â®</span> (edrophonium chloride).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<p class="First"><span class="Bold">HOW SUPPLIED </span>Pyridostigmine Bromide Tablets 60 mg are supplied as white, round compressed tablets debossed â€œcorâ€? over â€œ128â€? on one side and scored (quadrisect) on the other side.</p>
<p>They are supplied as follows:<br>Unit-Dose Box of 30Â Â Â Â Â Â Â Â Â Â Â Â (NDC 0179-0070-70)
</p>
<p>Store at 25Â° (77Â°F); excursions permitted to 15Â° - 30Â°C (59Â° - 86Â°F).Keep Pyridostigmine Bromide Tablets in a dry place. <br>Dispense in tight containers as defined in USP/NF.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-10"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Osserman KE, Genkins G. Studies in <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>: Reduction in mortality rate after crisis. <span class="Italics">JAMA.</span> Jan 1963; 183:97-101.</li>
<li>Osserman KE, Genkins G. Studies in <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. <span class="Italics">NY State J Med.</span> June 1961; 61:2076-2085.</li>
<li>Grob D. <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia gravis</span>. A review of pathogenesis and treatment. <span class="Italics">Arch Intern Med.</span> Oct 1961; 108:615-638.</li>
<li>Schwab RS. Management of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. <span class="Italics">New Eng J Med.</span> Mar 1963; 268:596-597.</li>
<li>Schwab RS. Management of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. <span class="Italics">New Eng J Med.</span> Mar 1963; 268:717-719.</li>
<li>Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. <span class="Italics">Clin Pharmacol Ther.</span> 1980; 28:No. 1, 78-81.</li>
<li>Miller RD. Pharmacodynamics and pharmacokinetics of anticholinesterase. In: Ruegheimer E, Zindler M, ed. <span class="Italics">Anaesthesiology.</span> (Hamburg, Germany: Congress; Sep 14-21, 1980; 222-223.) (Int Congr. No. 538), Amsterdam, Netherlands: Excerpta Medica; 1981.</li>
<li>Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F. Pyridostigmine kinetics in healthy subjects and patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. <span class="Italics">Clin Pharmacol Ther.</span> 1985; 5:495-501.</li>
</ol>
<div class="Figure"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9448c360-0ce2-42fe-9f0c-50f2159e8483&amp;name=Pyridostigmine-02.jpg"></div>
<p class="First">Manufactured and Distributed by:<br>Corepharma, LLC.<br>Middlesex, NJ 08846</p>
<br><p>REPACKAGED BY:<br>KAISER FOUNDATION HOSPITALS<br>LIVERMORE, CA 94551</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>Pyridostigmine tablets 60mg - 30 tablets in a Box-Unit Dose</h1>
<div class="Figure"><img alt="Container Label for 60mg, Box of 30 Unit-Dose" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9448c360-0ce2-42fe-9f0c-50f2159e8483&amp;name=Pyridostigmine-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PYRIDOSTIGMINE BROMIDEÂ 		
					</strong><br><span class="contentTableReg">pyridostigmine bromide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0179-0070(NDC:64720-128)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Pyridostigmine Bromide</strong> (Pyridostigmine) </td>
<td class="formItem">Pyridostigmine Bromide</td>
<td class="formItem">60Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White) </td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">cor;128</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0179-0070-70</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040457</td>
<td class="formItem">08/02/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>KAISER FOUNDATION HOSPITALS
							(053052619)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KAISER FOUNDATION HOSPITALS</td>
<td class="formItem"></td>
<td class="formItem">053052619</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>96e3b125-6174-429d-8140-421afe0427f0</div>
<div>Set id: 9448c360-0ce2-42fe-9f0c-50f2159e8483</div>
<div>Version: 1</div>
<div>Effective Time: 20100817</div>
</div>
</div>Â <div class="DistributorName">KAISER FOUNDATION HOSPITALS</div></p>
</body></html>
